Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.
Berger
M Z
MZ
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Kris
M G
MG
Gralla
R J
RJ
Marks
L D
LD
Potanovich
L M
LM
Dimaggio
J J
JJ
Heelan
R T
RT
D000225:Adenine; D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007094:Imides; D007364:Intercalating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D053644:Naphthalimides; D009367:Neoplasm Staging; D063065:Organophosphonates; D012074:Remission Induction
D000970:Antineoplastic Agents; D007094:Imides; D007364:Intercalating Agents; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine